Advanced Wound Care Market: Size, Growth and Where Diabetic Foot Ulcers Fit

Published estimates put the global advanced wound care market at about $11.7 billion to $16.4 billion in 2025 (IMARC Group; Global Market Insights), growing roughly 5% to 8% a year (IMARC Group; MarketsandMarkets). Global Market Insights puts the US market near $5 billion in 2024. Diabetes, aging, chronic wounds and Medicare payment changes drive the outlook.

How Big Is the Global Advanced Wound Care Market?

Commercial estimates of the global advanced wound care market for 2025 run from about $11.7 billion to $16.4 billion, depending on the publisher and what it counts. Forecasts reach roughly $18 billion to $27.5 billion by 2030 to 2034. These are commercial estimates, not audited data and not a forecast of any company's results.

Why the estimates differ: wound care market size versus advanced wound care

Scope explains most of the gap. Global Market Insights publishes two reports with different definitions: an advanced wound care report at $16.4 billion for 2025, and a broader wound care report at $26.3 billion that adds surgical and traditional wound care. Reports that count only dressings and devices also differ from those that add biologics, skin substitutes and topical agents.

Segments: the advanced wound dressings market, devices and biologics

Publishers typically divide the category into advanced dressings, therapy devices such as negative pressure systems, biologics and skin substitutes, and topical agents. In Global Market Insights' broader report, advanced wound dressings were the largest product segment, at 31.8% of the 2025 wound care market. Segment growth depends heavily on evidence and reimbursement. Our article Chronic Wound Treatment Options Compared explains how therapy classes differ.

How Big Is the Advanced Wound Care Market in US?

Estimates for US vary with scope. Global Market Insights valued the US advanced wound care market at about $5 billion in 2024, up from $4.8 billion in 2023. Its broader wound care report puts the US at $7.5 billion for 2025, and Fortune Business Insights estimates $7.89 billion for 2026. All are commercial estimates.

Wound care in US is paid for by Medicare, commercial insurers and the VA, and delivered in hospital outpatient departments, wound care centers, physician offices, home health and skilled nursing facilities. Medicare payment rules differ by setting, so a product's economics depend on where it is used.

What Is Driving Growth in Wound Care?

Four drivers recur in US data and market reports: diabetes prevalence, an aging population, chronic wound burden and payer policy. The first three expand the pool of patients at risk, while payer policy shapes what products can earn. Each driver below is sourced.

• Diabetes prevalence: The CDC estimates 40.1 million people in US had diagnosed or undiagnosed diabetes in 2023, including 29.1 million with a diagnosis.
• Aging population: The Census Bureau counted 61.2 million people age 65 and older in 2024, or 18.0% of the population, up 3.1% from 2023.
• Chronic wound burden: A Value in Health analysis found that nearly 15% of Medicare beneficiaries (8.2 million) had at least one type of wound or infection, with total Medicare spending estimated at $28.1 billion to $96.8 billion (2014 data).
• Payer shifts: CMS reports that Medicare Part B skin substitute spending rose from $256 million in 2019 to over $10 billion in 2024, and from January 1, 2026 most of these products are paid as incident-to supplies.

How payer pressure changes product economics

CMS says skin substitute prices "can reach more than $2,000 per square centimeter." Its 2026 rule sets an initial payment rate of $127.28 per square centimeter, geographically adjusted, for most products now classed as incident-to supplies, according to a law firm summary of the rule. Products covered by a biologics license continue under average sales price payment. CMS expects the change to cut Medicare spending on these products by nearly 90%.

In general terms, when payment is set independently of list price, revenue depends on cost of goods, handling and waste rather than on price. Market-size reports built on earlier pricing may therefore overstate the revenue pool for categories whose payment fell. This is analytical reasoning, not a sourced estimate.

Where Do Diabetic Foot Ulcers Fit in the Market?

Diabetic foot ulcers are a wound type within advanced wound care, and several publishers size them separately. Global diabetic foot ulcer market size estimates run from about $4.9 billion to $8 billion for 2025 to 2026, and US estimates from $1.5 billion to about $2.3 billion. Scopes differ, so they cannot be compared directly with advanced wound care totals.

• Straits Research (2025): $4.87 billion global and $1.50 billion in US; counts advanced dressings, biologics and therapy devices.
• Credence Research (2025): $5.64 billion global.
• Global Market Insights (2025): $6.95 billion global and $2.30 billion in US; counts commercial products and therapies used to manage diabetes-related foot ulcers.
• Fortune Business Insights (2025): $7.14 billion global; counts dressings, devices and active therapies such as skin substitutes and growth factors.
• Persistence Market Research (2026): $8 billion global.

US burden and Medicare cost

The same Value in Health analysis estimated Medicare spending on diabetic foot ulcers at $6.2 billion, $6.9 billion and $18.7 billion across three estimates based on 2014 data. AHRQ reported annual ulcer incidence of about 6% among Medicare beneficiaries with diabetes (2006 to 2008 data). For clinical context, see Diabetic Foot Ulcer Treatment in US: Current Options, Gaps and What Comes Next.

How Should Investors Read Wound Care Market-Size Reports?

Read the definition before the number. Check what the report counts, which year is actual versus forecast, whether revenue is measured at manufacturer or end-user level, and whether segments overlap. Treat the figure as an order-of-magnitude input, not a measure of any one company's opportunity.

• Definitions: The two Global Market Insights reports above differ by roughly $10 billion for the same year because of scope alone.
• Double counting: A product can sit in more than one segment, such as a dressing used with a therapy device. Check whether the report nets overlaps out.
• Forecasts versus actuals: Base-year figures are themselves modeled, and forecasts compound a growth rate over many years. Differences of a few points in growth rate compound into large differences by 2034.
• What a market number does not tell you: It does not show a company's share, pricing, reimbursement, clinical evidence or technical risk. A category's size says little about a preclinical candidate, which must first generate data.

Frequently Asked Questions

How big is the advanced wound care market?

Published 2025 estimates of the global advanced wound care market range from about $11.7 billion to $16.4 billion, depending on the publisher and scope.

How big is the advanced wound care market in US?

Global Market Insights estimated about $5 billion in 2024. Its broader wound care report estimated $7.5 billion for 2025.

What is driving wound care market growth?

Diabetes prevalence, an aging population, chronic wound burden and changing Medicare payment rules.

How big is the diabetic foot ulcer market?

Global estimates run from about $4.9 billion to $8 billion for 2025 to 2026, and US estimates from $1.5 billion to about $2.3 billion.

Why do market reports disagree?

They define the market differently, count different products and use different base years and growth assumptions.

About ZegeneX

ZegeneX is developing Zegen-X5, an investigational, preclinical, shelf-stable small-molecule topical therapy being evaluated for diabetic foot ulcers and other hard-to-heal wounds. Zegen-X5 has not been approved by the US FDA. See the ZegeneX clinical pipeline.

Related reading: Partnerships & Investor Relations | Chronic Wound Treatment Options Compared

This article is for informational purposes only and is not medical advice or investment advice.

Sources

Government and peer-reviewed sources

• CDC, National Diabetes Statistics Report
• US Census Bureau, Older Adults Outnumber Children in 11 States and Nearly Half of US Counties (June 26, 2025)
• CMS press release, October 31, 2025 (CY 2026 payment rule and skin substitutes)
• CMS, CY 2026 Physician Fee Schedule final rule fact sheet
• Nussbaum et al., An Economic Evaluation of the Impact, Cost, and Medicare Policy Implications of Chronic Nonhealing Wounds, Value in Health 2018
• AHRQ via NCBI Bookshelf, Incidence of diabetic foot ulcer and lower extremity amputation among Medicare beneficiaries, 2006-2008
• Law firm summary (not a primary source), Reed Smith, CMS reclassifies certain skin substitutes

Commercial estimates, not audited data

• IMARC Group, Advanced Wound Care Market
• Precedence Research via GlobeNewswire, Advanced Wound Care Market
• MarketsandMarkets, Advanced Wound Care Market
• Global Market Insights, Advanced Wound Care Market
• Global Market Insights, Wound Care Market
• Global Market Insights, Diabetic Foot Ulcer Treatment Market
• Fortune Business Insights, Wound Care Market
• Fortune Business Insights, Diabetic Foot Ulcer Treatment Market
• Credence Research, Diabetic Foot Ulcers Treatment Market
• Persistence Market Research, Diabetic Foot Ulcer Therapeutics Market
• Straits Research, Diabetic Foot Ulcer Treatment Market